Gonal-f Rff Pen is a drug owned by Emd Serono Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 02, 2024. Details of Gonal-f Rff Pen's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(9 years ago) |
Expired
|
| US5767067 | Follicle stimulating hormone and pharmaceutical compositions containing same |
Jun, 2015
(9 years ago) |
Expired
|
| US7446090 | FSH formulation |
Aug, 2019
(5 years ago) |
Expired
|
| US7741268 | Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant |
Apr, 2024
(5 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Gonal-f Rff Pen's patents.
Latest Legal Activities on Gonal-f Rff Pen's Patents
Given below is the list of recent legal activities going on the following patents of Gonal-f Rff Pen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Dec, 2021 | US7741268 |
| Expire Patent Critical | 07 Dec, 2020 | US7446090 |
| Maintenance Fee Reminder Mailed Critical | 22 Jun, 2020 | US7446090 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Dec, 2017 | US7741268 |
| Sequence Moved to Public Database | 25 Jun, 2010 | US7741268 |
| Patent Issue Date Used in PTA Calculation Critical | 22 Jun, 2010 | US7741268 |
| Recordation of Patent Grant Mailed Critical | 22 Jun, 2010 | US7741268 |
| Email Notification Critical | 03 Jun, 2010 | US7741268 |
| Issue Notification Mailed Critical | 02 Jun, 2010 | US7741268 |
| Sequence Forwarded to Pubs on Tape | 19 Apr, 2010 | US7741268 |
US patents provide insights into the exclusivity only within the United States, but Gonal-f Rff Pen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Gonal-f Rff Pen's family patents as well as insights into ongoing legal events on those patents.
Gonal-f Rff Pen's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Gonal-f Rff Pen's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 02, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Gonal-f Rff Pen Generics:
There are no approved generic versions for Gonal-f Rff Pen as of now.
Gonal-f Rff Pen Competitors
Understanding your competition is essential for market success. There are several other brand drugs using the same active ingredient (Follitropin Alfa/beta) as Gonal-f Rff Pen. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Emd Serono |
| ||
| Organon Usa Inc |
|
About Gonal-f Rff Pen
Gonal-F Rff Pen is a drug owned by Emd Serono Inc. Gonal-F Rff Pen uses Follitropin Alfa/Beta as an active ingredient. Gonal-F Rff Pen was launched by Emd Serono in 2019.
Approval Date:
Gonal-f Rff Pen was approved by FDA for market use on 25 November, 2019.
Active Ingredient:
Gonal-f Rff Pen uses Follitropin Alfa/beta as the active ingredient. Check out other Drugs and Companies using Follitropin Alfa/beta ingredient
Dosage:
Gonal-f Rff Pen is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 450 IU/0.75ML | INJECTABLE | Prescription | SUBCUTANEOUS |
| 900 IU/1.5ML | INJECTABLE | Prescription | SUBCUTANEOUS |
| 300 IU/0.5ML | INJECTABLE | Prescription | SUBCUTANEOUS |